Evidence map›Paper›PMID 40289651›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Palladium-Catalyzed Dual Csp

Jiahui Huang, Yuantao You, Yijian Ma, Xingying He, Yixiao Li, Arunachalam Kesavan, Chengzhi Jin, Chengshuo Shen, Min Zhang, Kedong Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Palladium-Catalyzed Dual CspAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiahui HuangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Yuantao YouGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Yijian MaSchool of Chemistry and Chemical Engineering, Zhejiang Sci-Tech University, Hangzhou, Zhejiang, 310018, China.
Xingying HeGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Yixiao LiGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Arunachalam KesavanGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Chengzhi JinGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Chengshuo ShenSchool of Chemistry and Chemical Engineering, Zhejiang Sci-Tech University, Hangzhou, Zhejiang, 310018, China.
Min ZhangKey Lab of Functional Molecular Engineering of Guangdong Province, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou, 510641, China.
Kedong YuanGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.ORCID https://orcid.org/0000-0001-9711-5629

Funding

High-level University Construction Fund of Guangdong Province 02-412-2202-2119National Natural Science Foundation of China 22471080Natural Science Foundation of Zhejiang Province LY23B040003Science Foundation of Zhejiang Sci-Tech University, China 22062026-Y
6 · The paper itself

Abstract

Transition-metal-catalyzed transformations offer a powerful approach to rapidly synthesize complex benzo-fused heterocycles, crucial for drug and material development. However, existing synthetic strategies face challenges such as limited functional group compatibility, reliance on complex ligands, and difficulties in controlling chemoselectivity with prefunctionalized substrates. Herein, a ligand-free Pd(II)/Cu(I) catalytic system is presented that facilitates reactions between arylsulfonyl chlorides and unactivated olefins under mild conditions, enabling the efficient synthesis of saturated benzo-fused six-membered heterocycles. This streamlined strategy employs dual Csp

Indexed as

arylsulfonyl chloridescyclizationheterocyclespalladium catalysis

Identifiers

PMID40289651
PMCPMC12224930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.